Przejdź do zawartości
Merck

1356960

USP

Leflunomide

United States Pharmacopeia (USP) Reference Standard

Synonim(y):

5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

200 MG

2370,00 zł

2370,00 zł


Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności

Zamów zamówienie zbiorcze

Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):
C12H9F3N2O2
Numer CAS:
Masa cząsteczkowa:
270.21
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:

Przejdź do

Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc

InChI

1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)

SMILES string

Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F

InChI key

VHOGYURTWQBHIL-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

leflunomide

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... DHODH(1723)

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 4

Ta pozycja
PHR1378Y0000654BP1233
Leflunomide United States Pharmacopeia (USP) Reference Standard

USP

1356960

Leflunomide

Leflunomide European Pharmacopoeia (EP) Reference Standard

Y0000654

Leflunomide

Leflunomide British Pharmacopoeia (BP) Reference Standard

BP1233

Leflunomide

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

manufacturer/tradename

USP

manufacturer/tradename

-

manufacturer/tradename

EDQM

manufacturer/tradename

BP

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

format

neat

format

neat

format

neat

format

neat

API family

leflunomide

API family

leflunomide

API family

leflunomide

API family

leflunomide

Gene Information

human ... DHODH(1723)

Gene Information

human ... DHODH(1723)

Gene Information

human ... DHODH(1723)

Gene Information

human ... DHODH(1723)

General description

Leflunomide is a drug with cytotoxic properties.[1] It is generally used as an immunosuppressive agent.[2]

Application

Leflunomide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.
Ta strona może zawierać tekst przetłumaczony maszynowo.

pictograms

Skull and crossbones

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Klasa składowania

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

flash_point_f

Not applicable

flash_point_c

Not applicable


Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumenty section.

Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

S Greene et al.
Biochemical pharmacology, 50(6), 861-867 (1995-09-07)
Leflunomide [HWA 486 or RS-34821, 5-methyl-N-(4-trifluoromethylphenyl)-4-isoxazole carboximide] is an immunosuppressive agent effective in the treatment of rheumatoid arthritis. In spite of its clinical potential, its mechanism of action has not been elucidated. Recent studies suggest that leflunomide may interfere with
Robert P Baughman et al.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 21(1), 43-48 (2004-05-07)
Leflunomide (Arava) is a cytotoxic drug which has been used as a single agent or in combination with methotrexate for the treatment of rheumatoid arthritis. It appears to have less toxicity than methotrexate. The use of leflunomide for sarcoidosis patients
Nicola Alcorn et al.
Drug safety, 32(12), 1123-1134 (2009-11-18)
Evidence is accumulating for the early sustained usage of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis. Leflunomide was licensed for the treatment of rheumatoid arthritis in 1998. Postmarketing surveillance, case reports and observational studies have highlighted less common or unexpected
W James Chon et al.
Expert review of clinical immunology, 7(3), 273-281 (2011-05-21)
Leflunomide is a synthetic isoxazole-derivative drug that possesses both immunosuppressive and antiviral properties. Although its only US FDA-approved indication is for the treatment of rheumatoid arthritis, accumulating clinical experience in addition to animal study data makes it an appealing option
Shigeko Inokuma
Expert opinion on drug safety, 10(4), 603-611 (2011-03-18)
Although disease-modifying antirheumatic drugs (DMARDs) are crucial for rheumatoid arthritis (RA) therapy, they have severe adverse events including interstitial pneumonitis (IP). DMARD-induced IP attracts attention because of its relatively high prevalence, occasionally fatal outcome and clinical features which are common

Questions

Reviews

No rating value

Active Filters

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej